SLC5A2 and type 2 diabetes mellitus: GLP-1 receptor agonists and SGLT2 inhibitors, newer therapeutic agents approved for type 2 diabetes, have demonstrated not only significant glucose-lowering effects but also notable extra-glycemic effects, including reductions in cardiovascular events [138,139,140,141,142,143,144,145,146,147,148,149].